Article

Androgen Receptor is a Determinant of Melanoma targeted drug resistance

2022-05-28

Abstract excerpt

Melanoma provides a primary benchmark for targeted drug therapy. Most melanomas with BRAF V600 mutations regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). However, nearly all relapse within the first two years, and there is a connection between pathways involved in BRAFi/MEKi-resistance and poor response to immune checkpoint therapy. We recently showed that androgen receptor (AR) activity is required for m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 502d806b-b7b9-5657-a18b-f317622bde11
DOI: 10.1101/2022.05.27.493720

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Androgen Receptor is a Determinant of Melanoma targeted drug resistanceDOI 10.1101/2022.05.27.493720Read

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapySemantic proximity Read

Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic ImplicationsSemantic proximity Read

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.Semantic proximity Read

Sustained Androgen Receptor signaling is a determinant of melanoma cell growth potential and tumorigenesisSemantic proximity Read

Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma.Semantic proximity Read

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint InhibitorsSemantic proximity Read

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?Semantic proximity Read

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.Semantic proximity Read

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read

ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read